Low Dose, High Impact: Microdosing, Content Uniformity, and Precision Control in TPDs

Key Takeaways

• Target protein degraders (TPDs), including PROTACs and molecular glues, remove disease-relevant proteins rather than simply inhibiting their activity, creating new opportunities for highly targeted therapies.

• Many TPD candidates require low-dose oral solid dosage formulations, making content uniformity, blend control, and analytical sensitivity critical to successful drug product development.

• TPD formulation can be complicated by poor aqueous solubility, limited permeability, high molecular weight, challenging particle morphology, and very low active pharmaceutical ingredient (API) concentrations.

• Enabling formulation technologies, including micronization, nanomilling, spray-dried dispersion, and hot-melt extrusion, may be needed to improve dissolution, solubility, bioavailability, and manufacturability.

• Successful TPD development requires early alignment among formulation design, excipient selection, high-potency containment, analytical method development, scale-up strategy, and GMP manufacturing requirements.

Target protein degraders (TPDs) are designed to remove disease-relevant proteins from the cell rather than simply block their activity like many traditional small molecule inhibitors. That distinction is central to both their therapeutic promise and their formulation complexity. Traditional inhibitors generally need to maintain sufficient target occupancy over time to suppress protein function. TPDs instead recruit the cell’s own protein degradation machinery, enabling a single degrader molecule to participate in multiple degradation events before it is cleared from the body.

Most TPDs work through the ubiquitin–proteasome system, a cellular pathway that tags unwanted or damaged proteins for destruction. In this process, E3 ubiquitin ligases help select target proteins and mark them with ubiquitin. Once a protein has been tagged, it is recognized by the proteasome, the cellular complex responsible for degrading proteins into smaller components that can be recycled or cleared.

The two best-known categories of TPDs are molecular glues and PROTACs (proteolysis-targeting chimeras). Molecular glues are small molecules that promote or stabilize interactions between an E3 ligase and a target protein, leading to ubiquitination and degradation. PROTACs are bifunctional molecules, meaning that one portion binds the target protein while another binds an E3 ligase, physically bringing the two into proximity so the target can be ubiquitinated.

This mechanism gives TPDs a pharmacological profile that differs from many conventional small molecule drugs. Because the degrader is not consumed in the degradation event, it can dissociate after recruiting the target protein to the E3 ligase and then engage another target molecule. This catalytic behavior helps explain why many TPD programs involve very low drug loads and low administered doses. It also explains why precision becomes so important in formulation and manufacturing: when the active pharmaceutical ingredient (API) is present at only a small fraction of the final dosage form, even minor variability in distribution can affect dose consistency, analytical control, and manufacturing robustness. For developers, the mechanism that makes TPDs compelling therapeutically therefore creates a practical development question: how can a highly precise, often highly potent, low-dose product be formulated and manufactured consistently from early clinical supply through commercial scale?

Beyond the challenge of low drug load, many TPDs are also difficult molecules from a drug product perspective. Many TPDs, particularly PROTACs, sit well outside the traditional physicochemical space described by Lipinski’s Rule of Five, which relates molecular weight, lipophilicity, hydrogen bond donors, and hydrogen bond acceptors to the likelihood of oral drug absorption. These molecules often have high molecular weights, complex and flexible structures, high melting points, and poor aqueous solubility. In practice, many behave like classic “brick dust” compounds, with limited dissolution in gastrointestinal fluids and, in some cases, limited permeability across biological membranes.

As a result, TPD development often requires more than conventional oral solid dosage (OSD) formulation. Many candidates fall into Biopharmaceutics Classification System (BCS) Class II or Class IV, where absorption may be limited by solubility, dissolution rate, permeability, or a combination of these factors. For developers, the central question is not only whether the molecule can be formulated but which barrier is most likely to limit performance in the body and which enabling technology is best suited to address it.

The Developability Classification System (DCS) provides a more practical framework for poorly soluble molecules by distinguishing between candidates whose absorption is primarily limited by dissolution rate and those limited by solubility itself. For DCS Class IIa compounds, which are slow to dissolve but ultimately soluble, the formulation strategy often focuses on increasing effective surface area. Micronization or nanomilling can improve dissolution by reducing particle size and increasing the surface area exposed to gastrointestinal fluids.

For DCS Class IIb compounds, the challenge is more fundamental. These molecules have inherently low solubility, often because of high crystallinity, and particle-size reduction alone may not be sufficient. In these cases, amorphous solid dispersion (ASD) technologies, such as spray-dried dispersion or hot-melt extrusion, may be needed to transform the API into a higher-energy amorphous form that can improve apparent solubility and support more effective absorption. This creates an additional layer of formulation complexity, because the enabling technology becomes part of the development strategy itself: the drug substance must be engineered into a form that can perform in the body while also remaining stable, manufacturable, and suitable for downstream OSD processing.

Uniform API distribution is essential for dose consistency, pharmacokinetic predictability, and product performance. For TPDs, however, achieving that uniformity can be especially difficult because the API may represent only a very small fraction of the final dosage form. In some cases, a formulation may contain only milligram- or low-gram quantities of API distributed across kilograms of blended material. At that scale, conventional blending can leave areas of higher API concentration, often referred to as “hot spots,” while other portions of the blend may contain too little API.

Formulations containing more than approximately 10% weight/weight API can often be managed using more traditional approaches to content uniformity. TPD formulations frequently fall below that threshold, with drug loads in the 1–5% range or lower. At these concentrations, the formulation and manufacturing process must be designed specifically to ensure consistent API distribution from the initial blend through the final tablet or capsule.

For blended products, achieving uniform distribution may require techniques like trituration and geometric mixing. In geometric mixing, an initial one-to-one blend of API and excipient is prepared to create a small concentrate. That concentrate is then blended with an additional portion of excipient, and the process is repeated in stages. Each step expands the concentrate gradually, almost like a snowball, until the API has been distributed throughout the larger batch. This staged approach helps avoid the uneven distribution that can occur when a very small amount of API is introduced directly into a much larger excipient blend.

In some cases, a carrier molecule is used to create the initial concentrate and improve API distribution. Colloidal silica, for example, can help bind hydrophobic API particles and support more even dispersion through the blend. A conical mill may be used to help bring the API and carrier into close contact before subsequent geometric mixing is performed to build the final formulation.

Other manufacturing strategies may also be useful depending on the API properties and target dosage form, including roller compaction and wet granulation. The appropriate choice depends on the API’s solubility, particle size, morphology, environmental sensitivity, and behavior during powder handling.

Particle size and morphology can strongly influence how a TPD behaves within a low-concentration OSD form. When the API represents only a small fraction of the formulation, its physical characteristics affect not only dissolution and bioavailability but also blend uniformity, flow, segregation risk, and manufacturability.

Micronized APIs can be especially challenging. Reducing particle size may improve dissolution by increasing surface area, but it also changes how the API interacts with excipients and carrier materials. If the API particles are extremely small, the excipient particle-size profile may need to be considered just as carefully as the API itself. In some cases, developers may explore particle-size engineering of commercial excipients to improve compatibility with the API. However, modifying an excipient can introduce regulatory uncertainty, including questions about whether the altered material could be viewed as a novel excipient. That risk must be weighed against the potential formulation benefit.

API morphology adds another layer of complexity. Needle-shaped particles, for example, can be difficult to distribute evenly because they may flow, align, bridge, or segregate differently than more uniform particles. When feasible, one strategy is to dissolve the API and recrystallize it into a more manageable form, then use an appropriate granulation process to help bind the API to the selected excipients or carrier materials. This can improve distribution and reduce the risk that the API will move unpredictably within the blend.

Roller compaction may also be used in certain cases to help break down problematic crystal structures and create a more processable intermediate. However, that approach must be evaluated against the API’s environmental sensitivities. Some TPDs may be vulnerable to moisture, heat, mechanical stress, or other processing conditions, so the formulation strategy must balance particle engineering with chemical and physical stability. The goal is not simply to reduce particle size or change morphology, but to create an API–excipient system that can be blended, processed, scaled, and controlled reproducibly.

In low-dose TPD formulations, excipients are not simply inactive ingredients. They are part of the control strategy that determines whether a small amount of potent API can be distributed, processed, and delivered consistently.

Excipient selection therefore requires attention not only to chemical compatibility, but also to grade, functionality, particle-size distribution, flow behavior, binding capacity, and performance in the intended manufacturing process. These factors become especially important when the API is hydrophobic, micronized, poorly flowing, or present at very low concentration. In such cases, the right excipient system can help support blend uniformity, reduce segregation risk, and improve downstream manufacturability.

Early process and excipient gap analyses are essential. These assessments help determine whether the selected materials can support the target dose, API properties, dosage form, and manufacturing route before the program advances too far. That upfront work can reduce the risk of later delays caused by poor content uniformity, inadequate process performance, or the need for reformulation.

For low-concentration TPD formulations, manufacturability cannot be evaluated only after formulation feasibility has been demonstrated. The process must be designed from the beginning with the intended equipment train, containment strategy, batch sizes, clinical supply needs, and GMP manufacturing path in mind. A formulation that performs well at small scale but requires fundamental redesign for GMP production can create avoidable delays as the program advances.

Scale-up planning is therefore a core part of formulation design. PCI Pharma Services supports this process using a database of equipment dimensions and operating characteristics to inform predictive modeling and scale-up decisions. This information can help identify which production units may be suitable for a given formulation and which process parameters are most likely to require adjustment as batch size increases.

Equipment similarity is particularly important for low-dose TPD products, because small changes in powder movement, mixing efficiency, granulation behavior, or transfer conditions can affect content uniformity. When small-scale and large-scale equipment come from the same manufacturer and are designed with comparable geometry, the development team has a stronger foundation for scale-up. For example, intermediate bulk containers across different sizes may share the same blending angle, helping preserve comparable powder movement as scale increases. Similarly, geometrically scaled high-shear mixers can help translate process behavior from development batches to larger GMP batches.

Process development can then proceed through either one-factor-at-a-time studies or multi-parameter design-of-experiments approaches, depending on the development stage, available API, timeline, and project objectives. For low-dose TPD formulations, this work is especially important because minor changes in mixing time, impeller speed, granulation conditions, transfer steps, or powder handling can influence uniformity and downstream performance.

Patient use also needs to remain part of the equation. Very low-dose products may offer flexibility in how the dose is presented, but the final dosage form must still be practical for the intended clinical use. Formulation design should therefore balance manufacturability with dose size, dose frequency, ease of administration, and patient compliance. The goal is a process and product presentation that are robust, scalable, operator-friendly, and suitable for long-term GMP manufacturing.

For novel TPD candidates, potency classification often begins before a complete toxicology package is available. In early development, preclinical toxicology data may be limited, and developers may have only partial information about the molecule’s mode of action, therapeutic indication, pharmacokinetics, half-life, and anticipated clinical dose. As a result, occupational exposure limits are often calculated using conservative safety factors to account for missing data.

This can place many TPDs into the highly potent or ultra-high potency category early in development. Very low dose itself can contribute to that classification, because potency assessments consider the relationship among biological activity, dose, exposure, toxicity, and available safety margins. For TPDs, the issue can be especially important because their catalytic mechanism may allow a single molecule to participate in multiple degradation events, while longer half-life or prolonged exposure can further increase occupational safety concerns.

That potency profile has direct implications for formulation and manufacturing. Low-concentration, highly potent drug products require processes that can achieve content uniformity while protecting operators, the product, the facility, and the environment. Techniques like geometric mixing, which may already be demanding in an open process, become more complex when performed within a rigid or flexible isolator. Limited glove mobility, constrained working space, material transfer steps, and the need to move intermediates between containment and blending equipment can make repeated mixing sequences physically demanding and operationally time-consuming.

These realities affect development timelines. Highly potent, low-dose products typically require longer setup, processing, transfer, and cleaning times than conventional oral solid dosage products. For TPD developers, potency therefore cannot be treated as a safety classification alone. It shapes equipment selection, process design, operator workflow, and the realistic timeline for moving from early development into GMP manufacturing.

The same low concentrations and high-potency profiles that complicate manufacturing also raise the analytical bar. For many low-dose oral solid dosage products, high-performance liquid chromatography (HPLC) or ultra-performance liquid chromatography (UPLC) can provide suitable analytical sensitivity and specificity. These methods are well established, broadly understood, and generally more straightforward to develop and validate than more complex analytical platforms.

As TPD concentrations move lower, however, conventional HPLC or UPLC methods may not always provide sufficient sensitivity. In those cases, liquid chromatography–mass spectrometry (LC-MS) may be required to detect and quantify the API accurately in the final dosage form. LC-MS may also be needed to support cleaning verification in a multi-product facility, where extremely small quantities of a highly potent compound may still represent a meaningful exposure or cross-contamination concern.

LC-MS can provide greater sensitivity, but it also introduces additional method-development and validation complexity. Standard chromatographic considerations still apply, including the physicochemical properties of the API and impurities, column chemistry, mobile phase composition, gradient conditions, and sample preparation. LC-MS methods add further variables, including ionization mode, source conditions, voltage settings, mass transitions, detector response, and matrix effects. Sample preparation can also be more involved, particularly when the method must reliably recover very small quantities of API from complex excipient matrices or equipment contact surfaces.

These factors can extend analytical development timelines, especially when methods must support both product testing and cleaning verification. For low-dose, high-potency TPDs, analytical strategy should therefore be aligned early with formulation design, manufacturing approach, and the overall control strategy so the product can be measured, released, and manufactured safely.

The TPD field is still relatively young, and continued progress in discovery is likely to create new formulation and manufacturing demands. As researchers gain a more sophisticated understanding of degrader design, target selectivity, E3 ligase recruitment, and structure–activity relationships, newer candidates are becoming increasingly potent, specific, and effective at very low doses. That progress is scientifically valuable, but it also pushes drug product development into more difficult territory.

For formulators, the challenge is practical as much as theoretical. A tablet containing an extremely small amount of API (e.g., 0.005 µg) may be very difficult or even impossible to manufacture consistently using conventional approaches. At that level, the physical challenge of distributing the API uniformly across the dosage form becomes severe. The occupational safety challenge may be equally limiting, because extremely potent molecules can require containment and handling controls that strain current manufacturing workflows.

These pressures make early communication among discovery chemistry, drug substance development, and drug product formulation teams essential. A TPD candidate may be highly promising from a biological standpoint, but if its potency, physical form, dose, solubility, morphology, or stability profile makes it impractical to formulate and manufacture, its clinical and commercial path becomes far more complicated. Designing TPDs with manufacturability and formulatability in mind from the outset can help prevent late-stage barriers and reduce the risk that a scientifically elegant molecule becomes difficult to translate into a viable product.

Future solutions may require new ways of presenting or processing extremely low-dose APIs. One possibility is linking a TPD to a larger molecular structure or otherwise modifying the drug substance presentation to make handling, distribution, and final dose formulation more manageable. Advances in high-speed API-in-capsule technologies may also help certain low-dose programs move more efficiently from early clinical development toward commercial supply.

At the far end of the potency spectrum, however, traditional human-centered manufacturing may eventually reach practical limits. If newer TPDs move into ultra-high-potency ranges that are increasingly difficult for operators to handle safely, automated or robotic systems may become more important for synthesis, formulation, containment, capsule filling, and other final-stage manufacturing activities. The long-term opportunity for the field is therefore not only to discover more precise degraders but to build the formulation, analytical, containment, and automation strategies needed to make those molecules developable at scale.

TPD development requires more than access to standard OSD manufacturing capacity. These programs often bring together low drug loads, poor solubility, challenging particle properties, high-potency handling requirements, analytical sensitivity needs, and demanding timelines. To advance successfully, developers need a formulation and manufacturing strategy that reflects the molecule’s properties, the intended dosage form, the clinical path, and the eventual requirements for GMP and commercial production.

PCI Pharma Services supports TPD developers through integrated drug development, manufacturing, and packaging capabilities, with particular experience in low-dose and high-potency OSD products. This integrated model can help reduce supply chain complexity and align formulation development, process design, clinical supply, scale-up, commercialization, and launch planning within a coordinated development path. For TPD programs, that alignment can be especially valuable because decisions made early in formulation can affect content uniformity, containment strategy, analytical method development, equipment selection, process robustness, and commercial manufacturability.

PCI’s Tredegar OSD site has several decades of experience working with highly potent compounds. The site combines specialized facilities, containment approaches, equipment design, training, and operational controls intended to protect employees, products, and the environment while supporting efficient high-potency manufacturing. This experience is particularly relevant for low-dose TPD programs, where achieving uniform API distribution may require repeated blending, contained transfers, specialized cleaning, and careful attention to operator workflow.

A key advantage is that development work can be performed on equipment aligned with the equipment used for GMP clinical and commercial batches. This supports earlier establishment of robust, scalable processes and reduces the risk that a formulation approach proven at small scale will need to be redesigned as the program advances. For low-dose TPDs, where minor process changes can affect content uniformity or manufacturability, that continuity can be critical.

PCI also complements its in-house high-potency and OSD capabilities through partnerships with companies that provide specialized enabling technologies. These partnerships support access to approaches like micronization, nanomilling, hot-melt extrusion, and spray-dried dispersion. Rather than forcing a molecule into a predetermined formulation pathway, PCI can evaluate the API, identify the primary development barrier, and select the most appropriate strategy for solubility, dissolution, permeability, particle engineering, and final dosage form performance.

For TPD developers, that molecule-led approach is essential. Some candidates may benefit from particle-size reduction, while others may require amorphous solid dispersion technologies or carrier-based strategies to support both bioavailability and content uniformity. By combining formulation design, high-potency handling, scalable process development, analytical awareness, and access to enabling technologies, PCI helps developers move challenging TPD candidates toward clinical and commercial readiness while managing risk across the development life cycle.